BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Staging
33 results:

  • 1.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Physiological Uptake Characteristics of breast on
    Zhang Y; Zhou Y; Tian R; Su M
    Mol Imaging Biol; 2023 Dec; 25(6):1045-1053. PubMed ID: 37945972
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. 68 Ga-FAPI-04 PET/CT in Selected breast cancer Patients With Low FDG Affinity : A Head-to-Head Comparative Study.
    Alçın G; Arslan E; Aksoy T; Cin M; Erol Fenercioğlu Ö; Beyhan E; Ergül N; Çermik TF
    Clin Nucl Med; 2023 Sep; 48(9):e420-e430. PubMed ID: 37351868
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Initial Evaluation of [
    Watabe T; Naka S; Tatsumi M; Kamiya T; Kimura T; Shintani Y; Abe K; Miyake T; Shimazu K; Kobayashi S; Kurokawa Y; Eguchi H; Doki Y; Inohara H; Kato H; Mori Y; Cardinale J; Giesel FL
    J Nucl Med; 2023 Aug; 64(8):1225-1231. PubMed ID: 37268427
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
    Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.
    Hirmas N; Hamacher R; Sraieb M; Ingenwerth M; Kessler L; Pabst KM; Barbato F; Lueckerath K; Kasper S; Nader M; Schildhaus HU; Kesch C; von Tresckow B; Hanoun C; Hautzel H; Aigner C; Glas M; Stuschke M; Kümmel S; Harter P; Lugnier C; Uhl W; Niedergethmann M; Hadaschik B; Grünwald V; Siveke JT; Herrmann K; Fendler WP
    J Nucl Med; 2023 May; 64(5):711-716. PubMed ID: 36581374
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis.
    Porpiglia M; Borella F; Chieppa P; Brino C; Ala A; Marra V; Castellano I; Benedetto C
    Tumori; 2023 Jun; 109(3):301-306. PubMed ID: 35751383
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Pretreatment evaluation of
    Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
    Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
    [No Abstract]    [Full Text] [Related]  

  • 9. Diagnostic value of
    Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L
    J Med Imaging Radiat Oncol; 2022 Sep; 66(6):731-737. PubMed ID: 34676675
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Simultaneous FAPI PET/MRI Targeting the Fibroblast-Activation Protein for breast cancer.
    Backhaus P; Burg MC; Roll W; Büther F; Breyholz HJ; Weigel S; Heindel W; Pixberg M; Barth P; Tio J; Schäfers M
    Radiology; 2022 Jan; 302(1):39-47. PubMed ID: 34636633
    [TBL